MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1

Cheng-Gang Li1,2, Meng-Fan Pu1,2, Chun-Zhu Li1,2

  • 1Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Acta Pharmacologica Sinica
|September 20, 2016
PubMed

Insights

MicroRNA-1304 (miR-1304) acts as a tumor suppressor in non-small cell lung cancer (NSCLC) by inhibiting cell growth and promoting apoptosis. It directly targets heme oxygenase-1 (HO-1), a key factor in NSCLC progression.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • MicroRNA-1304 (miR-1304) is implicated in various cancers, including non-small cell lung cancer (NSCLC).
  • Its precise role and direct targets in NSCLC require further elucidation.

Purpose of the Study:

  • To investigate the function of miR-1304 in NSCLC.
  • To identify and validate the direct target of miR-1304 in NSCLC cells.

Main Methods:

  • In vitro studies using NSCLC cell lines (A549, NCI-H1975).
  • Assays for cell proliferation, viability, apoptosis, and cell cycle.
  • Dual-luciferase reporter assay and CRISPR/Cas9 for target validation.
  • Analysis of miR-1304 and heme oxygenase-1 (HO-1) expression in NSCLC tissues.

Main Results:

  • Overexpression of miR-1304 reduced NSCLC cell proliferation, viability, and colony formation, while inducing apoptosis and G0/G1 cell cycle arrest.
  • Heme oxygenase-1 (HO-1) was confirmed as a direct target of miR-1304.
  • Restoring HO-1 expression counteracted miR-1304's inhibitory effects.
  • Suppression of miR-1304 increased HO-1 expression and promoted NSCLC cell growth.
  • NSCLC tissues showed decreased miR-1304 and increased HO-1 expression compared to normal lung tissues.

Conclusions:

  • MicroRNA-1304 functions as a tumor suppressor in NSCLC.
  • Heme oxygenase-1 is a direct target of miR-1304 in NSCLC.
  • miR-1304 represents a potential therapeutic target for NSCLC treatment.